BOSTON & MONTREAL, April 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, ...

Citing headwinds from the “anti Elon Musk crowd” and declining favorability among Tesla's (NASDAQ:TSLA) target demographic, ...

Mikaela Shiffrin's Comeback What could have been a season full of discontent turned into an opportunity for legendary skier Mikaela Shiffrin to rebuild and make ...

The dividends of renewable infrastructure investment trusts are at risk of growing more volatile as subsidies for clean ...

It was a historically difficult quarter for the EV maker, with tariffs and growing protests over Elon Musk's work with DOGE ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $26 and keeps a Buy rating on the shares.

Germany-based Deutsche Bank slashed its price target on TSLA stock to $345 from $420. Like Stifel, Deutsche Bank reduced its ...

Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA ...

Learn more about whether Stifel Financial Corp. or Victory Capital Holdings, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Stifel Financial Corp. or StepStone Group Inc. is a better investment based on AAII's A+ Investor ...

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA ...